The Efficacy Of Omalizumab In Patients With Moderate To Severe Allergic Asthma:a Meta Analysis Of Randomized Controlled Studies

Objective:To evaluate the efficacy of omalizumab in the treatment of moderate to severe allergic asthma.Methods:The databases published from established were retrieved from Embase,Web of science,Pubmed,Cochrane Library,CNKI,and CBM to collect randomized controlled trials.Then Review Manager 5.3 software was used for meta-analysis after literature screening,data extraction and literature quality evaluation by two researchers.Results:A total of 12 randomized controlled trials were included,including 4527 patients with moderate to severe allergic asthma,including 2578 patients in Omazumab group and 1949 patients in control group.Meta-analysis showed that compared with the control group,Omazumab could reduce the frequency of patients with one acute attack of asthma(RR =0.76,95%CI: 0.62-0.93,P=0.008)and the frequency of acute attack of asthma(WMD =-0.31,95%CI:-0.52～-0.10,P=0.04),improved AQLQ score(WMD =0.27,95%CI: 0.16-0.37,P <0000.1),and improved quality of life;There were no significant changes in the incidence of adverse reactions and serious adverse reactions(P =0.12,P=0.17).Conclusion:For patients diagnosed with moderate to severe allergic asthma,combined with omazumab on the basis of conventional treatment can benefit.For moderate-to-severe allergic asthma patients with frequent acute exacerbations or uncontrolled symptoms who have received standardized ICS+LABA therapy at medium and high doses,omazumab combination therapy can be considered after excluding factors such as poor medication compliance,incorrect inhalation techniques,smoking,co-existing diseases,and misdiagnosis.